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Genome editing, also known as gene editing, is a technique of genetic engineering that 
involves the alteration of an organism’s genetic structure by adding, deleting, changing or 
replacing individual nucleotides or sequences of DNA. Genome editing includes several 
different methods and tools, which can be used by breeders to alter the traits of crop 
plants and livestock animals. Genome-edited crops and food products are beginning to 
be commercialised, which raises questions around how the techniques and products of 
genome editing should be governed.
This briefing explains why the governance of genetic engineering is a topic of public 
interest and concern. It considers whether genome editing raises new issues relating to 
environmental and food safety, intellectual property rights or trade, and why genome 
editing applications may provoke public controversy. In particular, it discusses whether 
regulations and policies to govern the techniques, applications and products of genome 
editing should be any different from those applied to the previous generation of genetic  
engineering technology.
Introduction
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Within the past 25 years, several powerful new 
techniques of genome editing have emerged, 
which promise to have a significant impact on 
the genetic manipulation of crops and livestock. 
Most genome-editing techniques use nucleases, 
a type of enzyme that repairs genetic damage or 
performs immune functions in living organisms, 
to cut and reconnect targeted sections of DNA. 
Researchers have developed ways to exploit 
this capability to cut out or insert selected 
genetic sequences, or to ‘knock out’ or modify 
the expression of specific genes. These novel 
techniques of genetic engineering may be used, 
either to generate mutations (i.e. to induce 
genetic variation that could be a source of valuable 
traits), or to insert or replace individual genes or 
sequences of interest (which could be transgenes 
taken from another organism).
In 2012, a paper in the journal Science reported 
that a tool known as CRISPR-Cas9 could be used 
as a versatile and efficient genome-editing tool. 
CRISPR stands for Clustered Regularly Interspaced 
Short Palindromic Repeats. The technique uses 
an endonuclease or ‘restriction enzyme’ to cut the 
genome in a specific location. These restriction 
enzymes are known as Cas (CRISPR-associated) 
proteins. While the CRISPR tool recognises the 
sequences of interest, the Cas proteins cut the 
DNA strands. Experiments using the restriction 
enzyme Cas9 have stimulated a rapidly growing 
body of research studies, but other numbered Cas 
proteins are also being investigated.
Background
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Should the techniques and products of genome 
editing be considered essentially the same as, 
or in specific respects different from, previous 
generations of modern biotechnology? Do CRISPR 
and other genome-editing methods raise new 
societal concerns or different public policy issues, 
compared to other methods of genetic engineering 
or mutation breeding? These questions are 
already lively topics of debate. In this briefing 
note, we examine reasons why genome editing 
could warrant special considerations from the 
perspectives of biology, political economy  
and geopolitics.
A key frame of comparison is with the way that 
societal stakeholders, policy frameworks and legal 
arrangements have treated a previous generation 
of genetic engineering, which is often referred 
to in public debate by the shorthand term GMOs, 
or genetically modified organisms. However, 
some stakeholders might argue that it would be 
more appropriate to compare the genetically 
engineered organisms produced using new 
genome editing techniques with ones developed 
using mutation breeding. Mutation breeding is 
an established technique used in crop breeding, 
which uses radiation or chemicals to stimulate 
genetic mutations. These alternative frames for 
comparison could have material consequences 
in the real world: in some jurisdictions, genetic 
modification has attracted special regulations  
that have not been applied to mutation  
breeding techniques.
Genome editing, genetic engineering, 
genetic modification…
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In practice and in legal frameworks, the term GMO 
has come to refer to organisms produced using 
some specific techniques, which incorporate 
genetic material transferred from another 
organism. Some people referred to GMOs as 
transgenics, because they contained these 
transferred genes or ‘transgenes’.
Before the methods of genome editing were 
developed, the principal techniques used to 
create transgenic organisms involved physically 
smashing genetic material together in living cells 
– a technique known as ‘biolistics’; or using a 
bacterium (usually Agrobacterium tumefaciens) to 
carry genes into plant cells and splice them into 
the genome of the host.
An example of a commercial GMO is ‘Bt cotton’, a 
type of cotton that incorporates genes originally 
obtained from a soil bacterium called Bacillus 
thuringiensis (Bt). A famous experimental case 
involved introducing genes from a flounder (a 
type of fish) into a strawberry, in the hope that the 
transferred genes would allow the strawberries 
to resist frost. As these examples illustrate, a 
factor that attracted much attention and caused 
some concern was that these techniques could 
be used to transfer DNA between organisms that 
were unrelated genetically. They produced types 
of genetic recombination that could not have 
happened without human intervention.
It is widely understood that public concerns 
about GMOs have to do with the perceived 
‘unnaturalness’ of these novel genetic mixtures. To 
help overcome these misgivings, some scientists 
have proposed new terminology to distinguish 
between different products of genetic engineering, 
based on the origin of the introduced DNA. 
Alongside transgenesis (where the introduced 
genes originated in a sexually incompatible 
organism), the terms intragenesis and cisgenesis 
have been proposed to designate specific types 
of genetic recombination, where the genes or 
sequences concerned originated in the same 
organism or from a sexually compatible gene pool. 
The idea is that intragenic and cisgenic organisms 
ought to provoke less concern among the public 
and consumers – and therefore should attract 
more permissive regulation.
Genetic engineers and regulatory scientists have 
categorised genome editing processes into three 
types: SDN-1, SDN-2 and SDN-3 (the abbreviation 
SDN stands for ‘site-directed nuclease’). The 
distinction depends on the mechanism used to 
reconnect the genome after it has been cut by the 
restriction enzyme. With SDN-1, the organism’s 
own cellular repair mechanisms make the repair: 
this process is prone to create random mutations, 
thereby generating genetic variation that could 
prove useful in a breeding programme. With SDN-
2 and SDN-3, the genetic engineers construct a 
template which tells the organism how to repair 
Differences in biology?
itself. When the changes to the genome are quite 
small, the modification is classified as SDN-2. 
Genetic engineers argue that the small genetic 
changes that result from SDN-1 and SDN-2 
procedures are similar to mutations that could 
have occurred in nature, so that less stringent 
regulation is appropriate for these organisms. 
SDN-3 is the label given to procedures that involve 
the introduction of longer genetic sequences, 
which could come from a sexually incompatible 
organism. 
 
Evidently, the transgenic–cisgenic–intragenic and 
SDN-1, -2 and -3 schemas can help to distinguish 
conceptually between products of genetic 
engineering based on whether they incorporate 
new genetic material. However, they might not 
help society to distinguish genome editing from 
older genetic engineering techniques. While 
genome editing can be employed, as its name 
implies, only to delete or rearrange individual 
bases or short segments of existing DNA, it can 
also be used to introduce genetic material from 
another organism, which could include a sexually 
incompatible species. This implies that scientists 
can use genome editing to create organisms 
that might be considered intragenic/cisgenic or 
transgenic, according to the above schema. Yet 
the technique used (employing nucleases to cut 
and reconnect genetic sequences) is certainly 
different from the biolistics- and Agrobacterium-
mediated methods that were used to create earlier 
generations of GMOs. It still remains to be teased 
apart which aspects of genome editing biology (if 
any) might be thought to matter from scientific, 
societal and regulatory points of view: the specific 
techniques employed; the sources of genetic 
material used, transferred and/or transformed; 
the nature and extent of the transformations 
made; or some combination of these three.
Some commentary on genome editing addresses 
another issue that is believed to be a source of 
public concern about GMOs: namely, that genetic 
engineering using biolistics or Agrobacterium 
produces random, unpredictable changes in 
DNA. (The same concern worries some critics 
of mutation breeding too.) While it is true 
that the sites of genetic recombination using 
these methods are unpredictable, in practice 
the transformation is replicated multiple 
times, and the mass of transformed material 
that results is screened and analysed to 
check where the introduced genes have been 
incorporated and to see how the insertions 
have affected the expression of genetic traits. 
Only the transformations that look promising 
are kept for further development and eventual 
commercialisation.
Genome editing has been described as a more 
precise and controllable method of genetic 
engineering, because tools such as CRISPR can 
be programmed to target a specific site in the 
genome, cut a chosen link in the DNA chain, and 
reconnect the cut pieces – removing, inserting or 
rearranging genes in the process – in quite precise 
and predictable ways. Again, things are slightly 
more complicated in practice. Research has found 
that CRISPR can produce unintended effects, both 
at the target site and in other places along the 
genome. Scientists argue that these issues can be 
managed by carefully programming the CRISPR-
Cas tools, and by screening the transformed 
organisms to ensure that the alterations are as 
desired and intended.
6  |  Genome Editing in Agriculture: Issues for Policy and Regulation  
7  |  Genome Editing in Agriculture: Issues for Policy and Regulation  
In the West, many of the first generation of 
commercial GM crops were developed mainly by, 
or with the backing of, large agribusiness-and-
biotechnology companies.1 These companies’ 
ability to dominate the new market for genetically 
modified (GM) crops was enabled and assisted 
by several factors that had to do with the 
contemporary political economy of modern 
biotechnology. Key among these were the ability 
to obtain patents on GM products, which allowed 
them to control access to commercially valuable 
transgenic material. Developing and applying the 
novel technology required some big investments 
in scientific laboratories and greenhouses, which 
were beyond the reach of small players. The big 
firms also used their spending power to purchase 
small biotechnology startups in order to gain 
control of their transgenic technologies, and to 
purchase big seed companies in order to have 
access to their stocks of valuable germplasm and 
to use their sales and distribution networks to 
reach farmers with the new seeds.
Equipped with these advantages, a handful of 
large transnational companies has dominated 
the market for transgenic crops and traits, 
driving a rapid and significant concentration of 
the seed industry. In this context, an ongoing 
source of concern has been the difficulty faced 
by smaller firms and public-sector plant breeders 
seeking access to transgenic breeding material 
on favourable terms. Another concern in some 
markets is that commercial farmers may have 
fewer choices in the seeds they can plant, and the 
associated technologies, such as herbicides, which 
they are permitted or obliged to use alongside 
proprietary GM cultivars.
There is much excitement around the potential for 
genome editing to improve the speed, precision 
and effectiveness of crop breeding programmes, 
compared to the first generation of genetic 
engineering techniques. The procedures involved 
are also expected by some stakeholders to be 
significantly less expensive than classical genetic 
engineering, making them more affordable for use 
by small and medium enterprises and by public 
sector organisations. If these predictions are 
correct, genome editing could make improved 
cultivars easier and cheaper to develop, which 
could undermine the dominance of the big 
biotechnology companies and improve the 
supply of varieties intended for poorer and 
economically marginalised farmers. However, 
these expectations that the technology will be 
more accessible have been questioned by some 
commentators, analysts and campaigners. 
In particular, concerns have been voiced that 
intellectual property rights over key aspects 
of CRISPR technology could impede scientific 
research and technological innovation. A related 
question is whether genome-edited organisms 
could be amenable to patenting in the same way 
as classical GMOs. There has been some debate 
about this issue, but the likely implications are 
A transformed political economy?
1 In China, public sector researchers and state-controlled companies played the leading roles.
unclear. Some commentators have suggested that 
the techniques involved in genome editing make 
the transformed organisms intrinsically harder 
to identify as products of genetic engineering. 
Unless a plant contains genetic sequences that 
have been patented or perhaps lodged with an 
agency that regulates seed or plant breeders 
rights – processes which require the developers 
to describe the genetic identity of the cultivar in a 
public register – it may be practically impossible 
to identify that the genetic sequences found in 
the plant have been modified with genome editing 
tools. In principle, the novel sequences might have 
arisen from a natural mutation or conventional 
selective breeding. This could make it harder for 
breeders or seed companies to claim or enforce 
proprietary rights over some kinds of cultivars 
(e.g. intragenic varieties). If so, some applications 
of genome editing technology might be more 
readily accessible than classical GMOs to small 
firms and public breeders. The actual implications 
may depend on how intellectual property rules are 
framed and enforced in each jurisdiction. 
Similar issues might arise with regard to the 
responsible stewardship of genome-edited 
organisms. A lively and contentious debate has 
surrounded the possibility that GMOs released 
into farming and food systems could cause 
harm to the environment or to consumers, and 
some stakeholders have similar concerns about 
genome edited organisms. If such organisms are 
difficult to identify and trace in the market or the 
environment, it could make regulatory oversight 
difficult or impossible. Would it then be practical 
or appropriate for governments to seek to make 
seed companies or merchants responsible or 
legally liable for harm that might be caused by 
genome edited varieties that they have released?
The resolution of these questions could have 
substantial implications for the shape and 
organisation of an emerging market for genome-
edited plant varieties. Besides ensuring that 
genome-edited organisms can be released into 
the environment and food chains safely and in the 
public interest, policy frameworks and regulatory 
regimes will in part determine whether, and 
on what terms, it may be practical, affordable 
and profitable for various public and private 
stakeholders to develop and release genome-
edited crop varieties. It remains to be seen what 
kinds of business models might emerge for a 
commercial trade in genome-edited crop varieties, 
or whether they will be the same as those for 
earlier types of GM cultivar, which typically rely on 
controlling access to proprietary genes via patents 
and contracts. Might they follow novel competitive 
strategies that deliver value to seed companies, as 
well as farmers and consumers, in other ways?
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The classical techniques of genetic engineering 
were developed during the 1980s and the first 
GM crop varieties were commercialised in the 
1990s. The GM crop economy emerged in the 
aftermath of the Cold War and the inauguration 
of the World Trade Organisation (WTO). This was 
the era of economic globalisation, guided along 
neoliberal lines. Countries around the world 
opened their markets to international trade and 
foreign investment, including populous nations 
such as India and China. The North American 
Free Trade Agreement (NAFTA) was implemented, 
the European Union’s (EU) single market was 
established, and various other regional trade 
agreements were concluded. Commercial 
agribusinesses were able to enter new markets and 
expand transnationally. The international trade in 
agricultural products was never wholly liberalised, 
but flows of agricultural products increased 
markedly, including horticultural exports from 
sub-Saharan Africa into Europe.
Against this background of market opening and 
globalisation, the trade in GMOs proved to be 
controversial and the world market became 
segmented into countries that embraced the 
new technology enthusiastically and those that 
proceeded much more cautiously. In particular, 
the EU market remained largely resistant to the 
wide commercialisation of GM crops and foods. 
This created tension between the EU and the USA 
and affected flows of commodity exports, such 
as soybeans grown in South America that were 
routed towards North American and other markets 
instead of European destinations.
Meanwhile, transgenic soybeans, maize, cotton 
and canola began to be planted widely in North 
and South America and Australia. Transgenic 
cotton was commercialised in China, South Asia 
and a handful of African countries. GM varieties 
of maize were planted in South Africa. Elsewhere, 
transgenic varieties of a few minor crops, such as 
papaya, were cultivated on small areas. However, 
the slow expansion of the global market for 
GM crops undoubtedly disappointed the early 
expectations of corporate managers and investors. 
Transgenic cultivars of wheat and rice have not 
yet been cultivated anywhere on a significant 
scale. Bt cotton has been planted on large areas 
in China, India, Pakistan and South Africa, but 
commercialisations of transgenic cotton and 
maize among small-scale farmers in South Africa 
and Bt cotton in Burkina Faso fell short of the 
developers’ expectations.
Meanwhile, farmers in countries that embraced 
GMOs in agriculture, such as the USA and Canada, 
have grappled with accumulating challenges in 
their farming systems, such as the emergence 
of herbicide-tolerant weeds, and insects that 
have developed resistance to Bt crops. Newer 
transgenic crop varieties have been introduced 
to help manage these issues, but some farmers 
are finding that the costs and complexity of 
cultivation in GMO-centred production systems 
A transformed geopolitical context
are increasing. For some farmers and investors 
in GM crop technologies, not to mention many 
environmentalists and some consumers, the early 
promises of GM crop technology were overstated.
Today’s geopolitical context is substantially 
different from the situation that surrounded the 
commercial release of GMOs during the 1990s 
and 2000s. It is an open question whether this 
significantly altered geopolitical landscape has 
implications for the potential commercialisation 
of genome-edited crops and foods in different 
jurisdictions around the world. However, the global 
context is different enough to assume that it could 
make a substantial difference to the prospects 
for developing and releasing new genetically 
engineered organisms.
Since the global financial crisis of 2008, and 
especially in the last half decade, the rules-based 
international trade regime shepherded by the 
WTO is being undermined by countries that have 
started to adopt more nationalist and mercantilist 
policies on trade, notably the United States. In 
the global South, rising powers such as China, 
Brazil and India – all of which have significant 
domestic capacity in biotechnology – have become 
increasingly important as trading partners, 
investors and aid donors to poorer countries, 
particularly in sub-Saharan Africa.
Meanwhile, even as the scientific evidence and 
consensus on the causes of global climate change 
and its potential impacts on agriculture and 
food security have strengthened and deepened, 
multilateral action to reduce greenhouse gas 
emissions and implement adaptation measures 
has been faltering and is being undermined. The 
Covid-19 pandemic has led food system experts 
and policy analysts to highlight the fragility and 
vulnerability of global food production systems 
and food security.
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The European Court of Justice (ECJ) ruled in 
July 2018 that genome-edited crops should be 
regulated under the same rules as genetically 
modified organisms (GMOs) within the EU single 
market (see Briefing 2).  The United Kingdom has 
left the EU, and the British government intends 
to adopt a permissive approach to genome edited 
crops and foods. If it does so, the UK will align 
itself with the USA instead of the EU, and its 
domestic agriculture and its trade relations will be 
significantly affected (see Briefing 3). Whether the 
EU’s internal policies on agriculture and food will 
be affected by Brexit remains to be seen.
The ECJ ruling has been criticised by some 
stakeholders and praised by others. It is 
contentious because it has implications for 
the development and application of genome 
editing techniques and products within the EU 
(and possibly the UK), and because European 
rules will have knock-on effects for the trade in 
agricultural products across the Atlantic and the 
Mediterranean. The EU policies and regulations 
governing genome editing in agriculture may also 
influence African nations that export agricultural 
products to European countries, as well as those 
which receive aid and technical support from 
Europe.
Societal debates and conflicts about genome 
editing, like previous struggles over GMOs, 
are about much more than the technical 
characteristics of specific products or processes. 
The debates raise large questions about the 
democratic governance of emerging technologies, 
ethical dimensions of human–nature relations, 
policy questions about land use, consumption 
and food security, and questions of social justice 
relating to the distribution of socio-ecological and 
economic costs and benefits. More broadly they 
concern the shaping and direction of alternative 
future pathways for agriculture and food. 
Emerging questions for Europe and the UK
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The GEAP3 Project Policy Hub
The Genome Editing and Agriculture: Policy, Practices and Public Perceptions (GEAP3) network is an 
international research consortium that brings together social scientists, policy experts and bio-scientists to 
explore the domestic and international ramifications of the EU’s policy and regulatory approach to genome 
editing in agriculture. The network is exploring and analysing key developments in genome editing and their 
implications for agriculture through three hubs: policy, practice, and public perceptions.
The GEAP3 Policy hub is exploring systematically the implications of the EU’s regulatory approach to genome 
editing. The hub is examining how competing visions for the governance of genome editing conflict or may be 
reconciled. For further information on the GEAP3 network and the Policy hub, please visit the project website at 
https://www.geap3.com
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